Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Myovant Sciences (MYOV : NYSE)
 
 • Company Description   
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.

Number of Employees: 579

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.08 Daily Weekly Monthly
20 Day Moving Average: 999,831 shares
Shares Outstanding: 95.33 (millions)
Market Capitalization: $960.95 (millions)
Beta: 2.79
52 Week High: $27.43
52 Week Low: $7.67
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.77% 19.14%
12 Week -22.22% -14.49%
Year To Date -35.26% -20.90%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR
-
LONDON,X0 SW1Y 4LB
GBR
ph: 44-20-7400-3351
fax: -
investors@myovant.com None
 
 • General Corporate Information   
Officers
David Marek - Principal Executive Officer
Myrtle Potter - Chairman
Uneek Mehra - Principal Financial Officer
Terrie Curran - Director
Mark Guinan - Director

Peer Information
Myovant Sciences (CORR.)
Myovant Sciences (RSPI)
Myovant Sciences (CGXP)
Myovant Sciences (BGEN)
Myovant Sciences (GTBP)
Myovant Sciences (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G637AM102
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 95.33
Most Recent Split Date: (:1)
Beta: 2.79
Market Capitalization: $960.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.43 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 4.16
EPS Growth
vs. Year Ago Period: 29.21%
vs. Previous Quarter: 7.35%
Sales Growth
vs. Year Ago Period: 133.96%
vs. Previous Quarter: 5.74%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -32.54
12/31/21 - -33.33
09/30/21 - -32.82
Current Ratio
03/31/22 - 1.95
12/31/21 - 2.14
09/30/21 - 2.44
Quick Ratio
03/31/22 - 1.92
12/31/21 - 2.11
09/30/21 - 2.42
Operating Margin
03/31/22 - -89.18
12/31/21 - -115.18
09/30/21 - -164.51
Net Margin
03/31/22 - -89.18
12/31/21 - -115.18
09/30/21 - -164.51
Pre-Tax Margin
03/31/22 - -87.00
12/31/21 - -114.16
09/30/21 - -164.13
Book Value
03/31/22 - -4.97
12/31/21 - -4.60
09/30/21 - -4.10
Inventory Turnover
03/31/22 - 1.87
12/31/21 - 1.67
09/30/21 - 1.22
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©